Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P10828

UPID:
THB_HUMAN

ALTERNATIVE NAMES:
Nuclear receptor subfamily 1 group A member 2; c-erbA-2; c-erbA-beta

ALTERNATIVE UPACC:
P10828; B3KU79; P37243; Q13986; Q3KP35; Q6WGL2; Q9UD41

BACKGROUND:
The Thyroid hormone receptor beta, alternatively named Nuclear receptor subfamily 1 group A member 2, c-erbA-2, or c-erbA-beta, serves as a critical transcription regulator. It binds thyroid hormones like triiodothyronine and thyroxine, modulating gene expression.

THERAPEUTIC SIGNIFICANCE:
Linked to disorders like generalized thyroid hormone resistance and selective pituitary thyroid hormone resistance, understanding the role of Thyroid hormone receptor beta could open doors to potential therapeutic strategies. Its involvement in these diseases underscores its significance in thyroid hormone function.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.